Approval is for use in myelofibrosis patients with anaemia regardless of prior myelofibrosis therapy
Opinion granted based on positive disease-free survival results from the Phase 3 KEYNOTE-091 trial
The Leaders of G20 met in New Delhi and committed to strengthening global health and implementing one health approach
Zilebesiran demonstrated an encouraging safety and tolerability profile in adult patients with mild-to-moderate hypertension
This exposé embarks on an illuminative journey, unfurling the crucial stratagems imperative for upholding public health, achieved through the unyielding fortress of pharmaceutical quality safeguards
AAT is a substantial socio-economic burden to livestock farmers in Sub-Saharan Africa, affecting and killing millions of cattle every year
This study showed that patients taking 75mg of Olpasiran previously every 12 weeks presented a 40–50% reduction in LP(a)
Reblozyl is the first and only therapy to demonstrate superiority compared to an erythropoiesis stimulating agent (ESA) in MDS-related anemia
The updated COVID-19 vaccine is tailored to the Omicron XBB.1.5 sublineage of SARS-CoV-2 and is recommended for individuals 6 months of age and older
Novo Nordisk’s GLP-1 Ozempic has reported a YoY increase in revenue from $2.1 billion to $3.2 billion
Subscribe To Our Newsletter & Stay Updated
